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Table　1　The relationship between PC20 and the variables
obtained by spirometry
R p value
FEV1 0.1412  0.0639 ns
FEV1/FVC 0.2370  0.0017 **
FEV1 %pred. 0.4618 <0.0001 ***
PEF 0.1803  0.0176 *
PEF %pred. 0.3988 <0.0001 ***
FEF50 0.2940 <0.0001 ***
FEF50 %pred. 0.4769 <0.0001 ***
FEF75 0.1620  0.0332 *
FEF75 %pred. 0.4207 <0.0001 ***
FEF25 0.2997 <0.0001 ***
FEF25-75 0.2665 <0.0004 ***
FEF25-75 %pred. 0.4982 <0.0001 ***
FEF75/Ht 0.1713  0.0242 *
FEF75/Ht %pred. 0.3391 <0.0001 ***
***p < 0.001,  **p < 0.01,  *p < 0.05.
Dear Editor
A Surrogate Marker of Airway
Hyperresponsiveness in Patients
with Bronchial Asthma
Airway hyperresponsiveness (AHR) is a characteris-
tic functional abnormality of asthma. In general, the
severity of the AHR correlates with the severity of
asthma.1 Therefore, the evaluation of AHR has been
reported to be useful for the diagnosis and manage-
ment of asthma.2-4 To evaluate the degree of AHR, an
inhalation challenge test (ICT) with a bronchocon-
strictor is usually performed. However, the ICT can
cause bronchospasm, and the method is complicated
for general practitioners. An alternative method to
evaluate the AHR more safely and easily is needed for
general practitioners.
The precise mechanism responsible for AHR has
not been clarified. However, factors altering the air-
way structure appear to be most closely related to
AHR.4 In this context, the baseline lung function is
known to be associated with AHR.5,6 However, there
have been no reports of using spirometry to predict
the degree of AHR. We investigated surrogate mark-
ers for AHR, and found that spirometry can predict
the degree of AHR, and might therefore be useful for
the management of asthma.
This study was a retrospective study. Asthmatic pa-
tients who underwent an ICT between January 2010
and September 2012 in The Fraternity Memorial Hos-
pital, Tokyo, Japan were continuously enrolled in this
study. Patients who had absolute contraindications
for the ICT based on the American Thoracic Society
(ATS) guidelines were not present in the population.7
The diagnoses were made based on the Global Initia-
tive for Asthma (GINA) guidelines.2 This study was
approved by the ethics committee of The Fraternity
Memorial Hospital.
Prior to ICT, the baseline lung function was meas-
ured with a spirometer (Auto Spiro AS-500; Minato,
Osaka, Japan). ICT was performed by modifying the
method according to the ATS guidelines.7 Histamine
dihydrochloride (Nacali Tesque, Kyoto, Japan) was
administered using a nebulizer, in doubling dose
from 0.039 to 20 mgml. The cut-off level of PC20 was
defined as 4 mgml.
The correlation coefficients were obtained by a
Spearman’s rank correlation test. The diagnostic per-
formance was expressed as the sensitivity, specificity,
and the area under the receiver operating character-
istic (ROC) curve. The optimal cut-off levels were de-
termined by the ROC curves.
The study subjects included 215 adult patients with
asthma, 112 males and 103 females, 25 of whom were
current smokers, 72 were ex-smokers and 118 were
nonsmokers. Eighty-four patients were newly diag-
nosed with asthma, and the other patients had re-
ceived treatment classified from Step 2 to Step 5 ac-
cording to the GINA guideline.2 The mean age of the
patients was 47.7 ± 16.2 years. The mean value of the
FEV1FVC was 84.3 ± 7.2%. The mean value of the
FEV1 %predicted was 85.3 ± 14.5%.
The correlation analysis between PC20 and the vari-
ables obtained by spirometry was performed in 173
patients whose PC20 was no more than 20 mgml. Al-
most all variables obtained by the flow volume curves
were correlated with the value of PC20 (Table 1) .
Among those, the Forced expiratory flow at 25-75% of
FVC (FEF25-75) %predicted showed the highest corre-
lation with PC20 (r = 0.4982, p < 0.0001), followed by
the FEF50 %predicted (r = 0.4769, p < 0.0001) and
FEV1 %predicted (r = 0.4618, p < 0.0001).
We selected the top three variables based on the
correlation analysis, the FEF25-75 %predicted, FEF50
%predicted and FEV1 %predicted, as candidates to
predict the asthmatics who would have a high degree
of AHR. When 4 mgdl was employed as a cut-off
level for PC20, the areas under the ROC curves of the
FEF 25-75 %predicted, FEF 50 % predicted and FEV 1
%predicted were 0.75, 0.75 and 0.76, respectively.
According to the ROC analysis, the optimal cut-off
levels of the FEF25-75 %predicted, FEF50 %predicted
and FEV1 %predicted were 73.5%, 77.5% and 84.5%, re-
spectively. When these cut-off levels were applied,
the FEF50 %predicted showed the highest sensitivity
and specificity, which were 70.4% and 74.0%, respec-
tively. The optimal cut-off levels, sensitivities and the
specificities obtained by the ROC analysis are shown
in Table 2.
Our results show that spirometry has the new po-
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Table　2　Diagnostic performance of FEF25-75 %predicted, 
FEF50 %predicted and FEV1 %predicted obtained by ROC
analysis
Cut-off Sensitivity (%)
Specifi city 
(%)
FEF25-75 %predicted 73.5 70.4 71.0
FEF50 %predicted 77.5 70.4 74.0
FEV1 %predicted 84.5 64.4 72.0
tential to predict the degree of AHR. Spirometry is a
safe and easy examination, which does not require
specialized personnel or laboratories. Our findings
are thought to be especially useful for general practi-
tioners. Among the variables obtained by spirometry,
we recommend that the FEF50 %predicted is the best
value to predict asthmatics with PC20 <4 mgml, be-
cause of its higher sensitivity and specificity. The
FEF25-75 %predicted and FEV1 %predicted also might
be good surrogate markers, but their sensitivity and
specificity were lower than those of the FEF50 %pre-
dicted.
We believe that 4 mgml is appropriate as a cut-off
level for confirming the presence of AHR, because a
PC20 value of 4-16 mgml is borderline AHR.7 In fact,
the target PC20 was 4 mgml in a recent report which
suggested the usefulness of a strategy to reduce the
AHR.3 Therefore, we employed 4 mgml as a cut-off
level for PC20 in the present study. Considering our
results, a FEF50 %predicted >77.5% might be useful as
a target value in the hospital, where the ICT cannot
be performed. Even when the cut-off levels of PC20
are set at different values other than 4 mgml, FEF50
%predicted maintains relatively fair sensitivities and
specificities. However, the higher PC20 is, the lower
the sensitivities and specificities tend to become
(data not shown).
The association between AHR and the baseline
lung function has long been recognized.5 The precise
mechanism underlying this relationship is still poorly
understood. However, as mentioned above, the struc-
tural changes in the airway are thought to have a
close association with the AHR.8 The inner airway
wall thickening amplifies airway smooth muscle
(ASM) shortening,9 and the hypertrophy and hyper-
plasia of the ASM increases the smooth muscle
strength.10 The adventitial thickening then uncouples
the airway from the surrounding parenchyma, result-
ing in a reduction of the tethering forces to oppose
the airway narrowing.8 These structural changes are
thought to influence the baseline lung function. Given
that we showed that almost all of the variables ob-
tained by the flow volume curve were correlated with
the PC20, these structural changes might be involved
in the development of AHR in the central airway, as
well as in the peripheral airway. Moreover, we
showed that the highest correlation was between the
PC20 and FEF25-75 %predicted, suggesting importance
of the small airway in the development of AHR as pre-
viously reported.11
We believe that the application of spirometry can
have a great impact on clinical practice, especially for
general practitioners. Moreover, the higher correla-
tion between the PC20 and variables responsible for
the peripheral airway status implies the importance of
the small airway in the development of AHR.
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